Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Adult participants diagnosed with either VABP or ventilated HABP requiring IV antibiotic therapy;~* Intubated and on mechanical ventilation at the time of randomization;~* New or progressive infiltrate on chest radiography consistent with pneumonia;~* Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial pneumonia.~Key Exclusion Criteria:~* History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics;~* Prior non-study antibiotics for \> 24 hours;~* Gram stain of lower respiratory tract specimen showing only gram positive bacteria;~* Active immunosuppression;~* End-stage renal disease or requirement for dialysis;~* Expected survival \< 72 hours;~* Severe confounding respiratory condition (i.e., chest trauma with paradoxical respiration);~* Known or suspected community-acquired bacterial pneumonia.~* Anticipated concomitant use of any of the following medications during the course of study therapy: valproic acid or divalproex sodium. Anticipated concomitant use of serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin 5-HT1 receptor agonists (triptans), meperidine, or buspirone during the course of linezolid treatment.~* Receipt of a monoamine oxidase inhibitor within 14 days prior to the first dose of study drug or anticipated concomitant use during the course of linezolid therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftolozane/tazobactam (Type: EXPERIMENTAL): Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
- Meropenem (Type: ACTIVE_COMPARATOR): Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).